PTO Affirms Shire’s Lialda Patent; First Decision In Kyle Bass IPR Case
Executive Summary
Patent board has instituted 19 other inter partes review proceedings sought by the hedge fund manager and declined to institute 14.
You may also be interested in...
US Patent Battles May Resume Next Congress; Reps Press For IPR Reform
10 New York representatives urge PTO to deny access to the inter partes review process to hedge funds and non-practitioners; generic companies join non-practicing entity Neptune Generics in challenging Lilly’s Almita patent.
Patent Score Card: Kyle Bass Gets 17 IPR Reviews Granted, 14 Denied
Bass wins review of four Acorda patents based on SEC registration filing; Patent Trial and Appeal Board declines to institute inter partes review of Enbrel patent and Insys' Subsys patents but okays trial on Juxtapid patents.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.